Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test - PubMed (original) (raw)
. 2005 Apr;179(1):198-206.
doi: 10.1007/s00213-004-2056-7. Epub 2004 Dec 4.
Affiliations
- PMID: 15821950
- DOI: 10.1007/s00213-004-2056-7
Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test
Thomas Steckler et al. Psychopharmacology (Berl). 2005 Apr.
Abstract
Rationale: Group I metabotropic glutamate receptor antagonists, which block both the mGlu1 and mGlu5 receptors, have been shown to have anxiolytic effects in the lick suppression test in rats.
Objective: The anxiolytic potential of the selective mGlu1 antagonist 3,4-dihydro-2H-pyrano[2,3]beta-quinolin-7-yl)(cis-4-methoxycyclohexyl)methanone (JNJ16259685) was investigated and compared with the mGlu5 antagonist MPEP.
Methods: Anxiety-related behaviour was assessed in lick suppression and in the elevated zero maze in rats. Non-specific effects on pain threshold, water intake and locomotor activity were also measured.
Results: Acute administration of JNJ16259685 or MPEP increased the number of licks (lowest active dose 2.5 mg/kg IP for each compound). JNJ16259685 did not increase water intake or reduce acute pain threshold, suggesting that the anxiolytic-like properties are specific. However, acute administration decreased locomotor activity. The effects of chronic administration of JNJ16259685 over 14 days (5 mg/kg bid) on lick suppression were comparable to those seen after acute administration, arguing against development of behavioural tolerance or sensitisation. Yet, there was a tendency for an increase in locomotor activity after cessation of chronic treatment. Acute co-administration of both JNJ16259685 and MPEP had additive effects on the number of licks. No anxiolytic-like properties of JNJ16259685 were observed in the elevated zero maze.
Conclusion: Our data suggest that the anxiolytic-like effects induced by group I metabotropic glutamate receptor antagonists are mediated through both mGlu1 and mGlu5 receptors. Rather than producing a general anxiolytic-like effect, the effects seen following mGlu1 antagonism seem task-dependent, as prominent effects were seen in a conflict procedure, but not in a task based on spontaneous exploration.
Similar articles
- Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task.
Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X, Lesage AS, Prickaerts J. Steckler T, et al. Behav Brain Res. 2005 Oct 14;164(1):52-60. doi: 10.1016/j.bbr.2005.05.010. Behav Brain Res. 2005. PMID: 16043241 - Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.
Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C. Spooren WP, et al. J Pharmacol Exp Ther. 2000 Dec;295(3):1267-75. J Pharmacol Exp Ther. 2000. PMID: 11082464 - Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wisłowska A, Płaźnik A, Bespalov AY, Danysz W. Pietraszek M, et al. Eur J Pharmacol. 2005 May 2;514(1):25-34. doi: 10.1016/j.ejphar.2005.03.028. Epub 2005 Apr 19. Eur J Pharmacol. 2005. PMID: 15878321 - mGlu5 receptor antagonists: a novel class of anxiolytics?
Spooren W, Gasparini F. Spooren W, et al. Drug News Perspect. 2004 May;17(4):251-7. doi: 10.1358/dnp.2004.17.4.829052. Drug News Perspect. 2004. PMID: 15334174 Review. - Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
Palucha A, Pilc A. Palucha A, et al. Pharmacol Ther. 2007 Jul;115(1):116-47. doi: 10.1016/j.pharmthera.2007.04.007. Epub 2007 May 13. Pharmacol Ther. 2007. PMID: 17582504 Review.
Cited by
- Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.
Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Krystal JH, et al. CNS Drugs. 2010 Aug;24(8):669-93. doi: 10.2165/11533230-000000000-00000. CNS Drugs. 2010. PMID: 20658799 Review. - Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.
Manka JT, Rodriguez AL, Morrison RD, Venable DF, Cho HP, Blobaum AL, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA. Manka JT, et al. Bioorg Med Chem Lett. 2013 Sep 15;23(18):5091-6. doi: 10.1016/j.bmcl.2013.07.029. Epub 2013 Jul 23. Bioorg Med Chem Lett. 2013. PMID: 23932792 Free PMC article. - Peripheral inflammation triggering central anxiety through the hippocampal glutamate metabolized receptor 1.
Wang JM, Wang YM, Zhu YB, Cui C, Feng T, Huang Q, Liu SQ, Wu QF. Wang JM, et al. CNS Neurosci Ther. 2024 Apr;30(4):e14723. doi: 10.1111/cns.14723. CNS Neurosci Ther. 2024. PMID: 38676295 Free PMC article. - Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5.
Felts AS, Saleh SA, Le U, Rodriguez AL, Weaver CD, Conn PJ, Lindsley CW, Emmitte KA. Felts AS, et al. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. doi: 10.1016/j.bmcl.2009.10.024. Epub 2009 Oct 9. Bioorg Med Chem Lett. 2009. PMID: 19854049 Free PMC article. - Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.
Thomas AM, Bui N, Graham D, Perkins JR, Yuva-Paylor LA, Paylor R. Thomas AM, et al. Behav Brain Res. 2011 Oct 1;223(2):310-21. doi: 10.1016/j.bbr.2011.04.049. Epub 2011 May 6. Behav Brain Res. 2011. PMID: 21571007 Free PMC article.
References
- Neuropharmacology. 2002 Aug;43(2):119-30 - PubMed
- Mol Pharmacol. 2002 May;61(5):1244-54 - PubMed
- J Pharmacol Exp Ther. 2002 Jan;300(1):149-56 - PubMed
- Trends Pharmacol Sci. 2001 Jul;22(7):331-7 - PubMed
- Neuropharmacology. 1999 Oct;38(10 ):1493-503 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical